Trial · NCT07217340
Feasibility of a Mental-Health Intervention Based on Contemplative Sleep Practices
NCT07217340, Early phase 1, Completed, Northwestern University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Feasibility of a Mental-Health Intervention Based on Contemplative Sleep Practices. Trials, record NCT07217340. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07217340
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Feasibility of a Mental-Health Intervention Based on Contemplative Sleep Practices
- NCT number
- NCT07217340
- Status
- Completed
- Phases
- Early phase 1
- Enrollment
- 25 participants, actual
- Lead sponsor
- Northwestern University
- Conditions
- Anxiety
- Interventions
- Dream Yoga Inspired Intervention, Sleep Health Enhancement program
- First posted
- 2025-10-15
- Last updated
- 2026-02-12
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Study Retention | 7 weeks (baseline to post-intervention) | Study retention as an outcome measure will be considered positive if ≥65% of participants complete data collection at both pre- and post-intervention. |
| Primary | Acceptability of the Intervention | 7 weeks (throughout the intervention period) | Acceptability will be assessed through composite measures of adherence to different elements of the intervention. The intervention will be considered acceptable if at least 70% of participants attend a minimum of five sessions. Adherence to supportive practices (dream journaling and online SHEP engagement) will also be assessed. These components will be considered acceptable if ≥75% of participants engage in Virtual Reality at a rate of ≥65%. |
| Primary | Tolerability of Dream Yoga Virtual Reality | 7 weeks (after each VR session) | Tolerability will be assessed using the Simulator Sickness Questionnaire (SSQ), which measures nausea, oculomotor strain, and disorientation. The intervention will be considered tolerable if fewer than 20% of participants report severe simulator sickness or withdraw due to VR-related adverse effects. Additional safety will be monitored through adverse event logs. |
| Primary | Study Retention | 7 weeks (baseline to post-intervention) | Feasibility will be assessed through study retention, defined as ≥65% of participants completing data collection at both pre- and post-intervention. |
| Secondary | Frequency of Lucid Dreaming | 7 weeks | Lucidity will be assessed with a composite of questionnaires at week 1 and measuring changes at week 7 and using self-reports of lucid dreams recorded in daily dream journals and/or nightly reports during the 7-week intervention. The outcome will be positive if one third of participants experience at least one lucid dream. Self-report Questionnaires: 1. Lucid Dreaming Skills Questionnaire (LUSK) 2. Lucid Dream Control-Specific Experiences (LDC-SE) |
| Secondary | Acceptability of the intervention | 7 weeks | Acceptability will also be measured with the Acceptability of Intervention Measure (AIM), a 4-item validated scale (1-5 Likert). The intervention will be considered acceptable if the mean AIM score is ≥4. |
| Secondary | Feasibility of the Intervention | 7 Week | Feasibility will be measured with the Feasibility of Intervention Measure (FIM), a 4-item validated scale (1-5 Likert). The intervention will be considered feasible if the mean FIM score is ≥4 ("agree" or "completely agree"). |
| Other | Change in Cognitive Flexibility Scale Score | 7 weeks (baseline to post-intervention) | Self-report measure assessing perceived ability to shift between thoughts and adapt to changing situations. |
| Other | Change in Generalized Anxiety Disorder Scale (GAD-7) Score | 7 weeks (baseline to post-intervention) | The Generalized Anxiety Disorder Scale - 7 item (GAD-7) is a self-report questionnaire used to assess anxiety symptoms over the past two weeks. Each item is rated on a 4-point Likert scale (0 = "not at all" to 3 = "nearly every day"). Total scores range from 0 to 21, with higher scores indicating more severe anxiety symptoms. |
| Other | Self-referential Processing: Composite od Subjective and Neural Markers | 7 weeks | Self-referential processing will be assessed using a composite of subjective and neurophysiological measures. Subjective measures include the Mindful Attention Awareness Scale (MAAS), the Cognitive and Affective Mindfulness Scale-Revised (CAMS-R), and the Nondual Awareness Dimensional Assessment (NADA) and Beck Cognitive Insight Scale. Neural activity associated with self-referential processing will be indexed by frontal midline theta power (4-7 Hz) during resting-state EEG. Increased frontal midline theta has been associated with internal attention, cognitive control, and self-related processing. A composite score may be computed via z-score standardization or used in exploratory correlation analyses. Higher mindfulness and nondual awareness scores, together with increased frontal midline theta, will be interpreted as indicators of enhanced self-referential regulation. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers7
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests2
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Probabilistic Reversal Learning | Other outcome | ConductCognition |
| Stroop Color-Word Test | Other outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07217340
GET https://conductscience.org/api/trials/v1/NCT07217340/registered